The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …

Although large surveys have documented the favourable safety profile of β 2-adrenoceptor
agonists (β 2-agonists) and, above all, that of the long-acting agents, the presence in the …

Summary Background The Single combination budesonide–formoterol inhaler Maintenance
And Reliever Therapy (SMART) regimen reduces severe asthma exacerbations in patients …

Background: The homozygous presence of the arginine-16 variant of the β2 adrenoceptor
gene ADRB2 reverses the benefits from the regular use of short acting β2 agonists in …

Beta-blockers are currently contraindicated in asthma because their acute administration
may be associated with worsening bronchospasm. However, their effects and safety with …

β2-adrenoceptor agonists are the first-line treatment of asthma and chronic obstructive
pulmonary disease (COPD), in which a short-acting β2-adrenoceptor agonist is used as …

Chronic use of inhaled beta-agonists by asthmatics is associated with a loss of
bronchoprotective effect and deterioration of asthma control. Beta-agonist-promoted …

BACKGROUND AND PURPOSE Inhalation of a β‐adrenoceptor agonist (β‐agonist) is first‐
line asthma therapy, used for both prophylaxis against, and acute relief of …

Background: The efficacy and safety of fluticasone propionate/formoterol fumarate
pressurized metered-dose inhaler (pMDI)(fluticasone/formoterol; Flutiform®; 100/10 µg bid) …

Background Alterations of B2 adrenergic receptor (β 2 AR) can modulate the severity of
asthma and the response to treatment. Therefore, we aimed to evaluate β 2 AR gene …